Two candidates for the coronavirus vaccine enter human trials

The World Health Organisation informed that around 60 are in the pre-clinical phase world-wide. One vaccine candidate being jointly developed by CanSino Biological Inc and Beijing Institute of Biotechnology has entered phase I human clinical trials. This vaccine uses a non-replicating viral vector as the platform (similar to that used in the Ebola vaccine) to develop a vaccine with an ‘Adenovirus Type 5’ candidate. Adenoviruses are the common cause of pneumonia and could deliver potential antigens to stimulate antibody production. Another vaccine being developed by the US-based biotech firm Moderna and National Institute of Allergy and Infectious Diseases also entered Phase I. This is a lipid nanoparticle encapsulated mRNA vaccine. The mRNA is an intermediary between the genetic information in DNA and the amino acid sequence of proteins. Such vaccines have not yet been approved for human use. India’s Serum Institute, Bharat Biotech, and Zydus Cadila are also working on the vaccine. Experts say only one in ten experimental vaccines make it to the regulatory approval.  

To know more about origin, virology of COVID-19, Click here

To know more about emerging themes in COVID-19, Click here

To know more about how WhiteCoats can help you in your professional advancement, visit

Want to set up an online consultation for your practice, Click here